These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 19774497)

  • 21. [High doses of immunoglobulin G in the therapy for severe forms of myasthenia gravis and Guillain-Barré syndrome].
    Lavrnić D; Romić M; Kacar A; Stojanović-Rakocević V; Stević Z; Vujić A; Basta I; Marjanović I; Bogdanović G; Apostolski S
    Vojnosanit Pregl; 2006 Jan; 63(1):37-42. PubMed ID: 16471247
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-based review of therapeutic plasma exchange in neurological disorders.
    Chhibber V; Weinstein R
    Semin Dial; 2012; 25(2):132-9. PubMed ID: 22277020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NKT and NKT-like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis and Guillain-Barre Syndrome.
    Zarobkiewicz MK; Morawska I; Michalski A; Roliński J; Bojarska-Junak A
    Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin use for neurologic diseases.
    Koski CL; Patterson JV
    J Infus Nurs; 2006; 29(3 Suppl):S21-8. PubMed ID: 16878852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome.
    Lizarraga AA; Lizarraga KJ; Benatar M
    Semin Neurol; 2016 Dec; 36(6):615-624. PubMed ID: 27907966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic apheresis in neurological disorders.
    Weinstein R
    J Clin Apher; 2000; 15(1-2):74-128. PubMed ID: 10767052
    [No Abstract]   [Full Text] [Related]  

  • 27. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases.
    Elovaara I; Apostolski S; van Doorn P; Gilhus NE; Hietaharju A; Honkaniemi J; van Schaik IN; Scolding N; Soelberg Sørensen P; Udd B;
    Eur J Neurol; 2008 Sep; 15(9):893-908. PubMed ID: 18796075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance immunosuppression in myasthenia gravis.
    Gotterer L; Li Y
    J Neurol Sci; 2016 Oct; 369():294-302. PubMed ID: 27653912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of autoimmune myasthenia gravis.
    Richman DP; Agius MA
    Neurology; 2003 Dec; 61(12):1652-61. PubMed ID: 14694025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current therapeutic options in severe Guillain-Barré syndrome.
    Shahar E
    Clin Neuropharmacol; 2006; 29(1):45-51. PubMed ID: 16518134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.
    Haupt WF; Rosenow F; van der Ven C; Birkmann C
    Ther Apher; 2000 Jun; 4(3):195-7. PubMed ID: 10910018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peripheral nervous system immunological disorder].
    Erazo Torricelli R
    Medicina (B Aires); 2018; 78 Suppl 2():82-87. PubMed ID: 30199371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic strategy in myasthenia gravis].
    Tranchant C
    Rev Neurol (Paris); 2009 Feb; 165(2):149-54. PubMed ID: 19233080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Guillain-Barré syndrome.
    McNair ND
    J Infus Nurs; 2013; 36(6):397-400. PubMed ID: 24202119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in patterns of progression in demyelinating and axonal Guillain-Barré syndromes.
    Hiraga A; Mori M; Ogawara K; Hattori T; Kuwabara S
    Neurology; 2003 Aug; 61(4):471-4. PubMed ID: 12939419
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids.
    Tannemaat MR; Verschuuren JJGM
    Neuromuscul Disord; 2020 Feb; 30(2):111-119. PubMed ID: 32007304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Select topics in neurocritical care.
    Noto A; Marcolini E
    Emerg Med Clin North Am; 2014 Nov; 32(4):927-38. PubMed ID: 25441043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders.
    Lehmann HC; Hartung HP; Hetzel GR; Stüve O; Kieseier BC
    Arch Neurol; 2006 Aug; 63(8):1066-71. PubMed ID: 16908731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Friendly fire on neurons: antibody-mediated diseases of the nervous system.
    Chang T
    Ceylon Med J; 2015 Dec; 60(4):121-5. PubMed ID: 26778390
    [No Abstract]   [Full Text] [Related]  

  • 40. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.